Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Telcagepant in Acute Migraine with Stable Vascular Disease
NCT00662818Phase 3Completed
- Sponsor
- Merck & Co.
- Start
- Mar 2008
- Primary completion
- Sep 2009
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, double-blind trial in migraine comparing Telcagepant -> Acetaminophen with Placebo/Acetaminophen -> Telcagepant (2 arms). Primary endpoints: Percentage of Participants With Pain Freedom at 2 Hours Post-dose, Number of Participants Who Experienced an Adverse Event at 14 days and 1 more. Started Mar 2008; status: completed.
02
Drugs
telcagepant
03
Conditions
migraine
Beyond the preview
Go deeper on NCT00662818.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00662818.